Immunotherapy is an effective treatment strategy for patients with advanced non‑small cell lung cancer (NSCLC). Although clinical trials on immunotherapy have provided promising results, real‑world research in clinical practice is needed to assess the effectiveness and safety of immunotherapy. The present study aimed to characterize real‑world outcomes in patients with advanced NSCLC treated with immune checkpoint inhibitor (ICI)‑based regimens. The medical records of patients with advanced NSCLC, who were treated with programmed cell death protein‑1 (PD‑1)/programmed cell death 1 ligand 1 (PD‑L1) inhibitors, were reviewed for data collection. The primary objectives were to evaluate progression‑free survival (PFS) and overall survival (OS). Therefore, multiple Cox regression models were used to investigate the predictive factors for survival outcomes. Furthermore, survival curves for PFS and OS were created using Kaplan‑Meier estimates and compared using the log‑rank test. The present study included a total of 133 patients with advanced NSCLC who received therapy with ICIs between January 1, 2019 and December 31, 2022. The final follow‑up date was August 24, 2023. The median PFS and OS times were 9.8 and 27.2 months, respectively. Univariate Cox regression analysis demonstrated that sex, clinical stage, PD‑L1 status, previous systemic therapy, and brain and liver metastases were associated with PFS, while Eastern Cooperative Oncology Group (ECOG) status, clinical stage, PD‑L1 status and brain metastasis were associated with OS. Furthermore, multivariate Cox regression analysis demonstrated that a PD‑L1 tumor proportion score (TPS) of ≥50% was an indicator of favorable PFS and OS. An ECOG performance status score of ≥1 was also associated with poor OS but not with PFS. Furthermore, brain metastasis was an indicator for poor PFS and OS, while liver metastasis was only associated with a poor PFS. Finally, the results of the present study demonstrated that PD‑L1 status was an independent predictor for PFS and OS in patients with advanced NSCLC, especially adenocarcinoma, who were treated with ICIs plus chemotherapy. The results also suggested that patients with a PD‑L1 TPS of ≥50% could benefit when the aforementioned regimens were administrated as a first‑line or later‑line therapy.

Related Articles